自血疗法治疗支气管哮喘缓解期的临床效果观察
|
摘要
目的探讨自血疗法治疗支气管哮喘缓解期的临床效果。方法选取2015年5月～2017年5月常德市第一中医医院呼吸科门诊及住院就诊的支气管哮喘缓解期患者120例,将患者按随机数字表法分为治疗组60例、对照组60例,对照组患者采用沙美特罗替卡松粉治疗,治疗组患者采用经络注血疗法治疗。比较两组的疗效及治疗前后的哮喘控制测试量表(ACT)评分。结果两组的疗效比较,差异无统计学意义(P>0.05)。两组治疗前、治疗后、随访1个月的ACT评分组间比较,差异均无统计学意义(P>0.05)。两组患者治疗后的ACT评分高于治疗前,差异均有统计学意义(P<0.05)。随访1个月,两组患者的ACT评分明显高于治疗前、治疗后,差异均有统计学意义(P<0.05)。结论自血疗法和沙美特罗替卡松粉治疗哮喘缓解期均具有效果,自血疗法和沙美特罗替卡松粉疗法的效果无明显差别。
Objective To investigate the clinical effect of autohemotherapy in the treatment of bronchial asthma at remittent period. Methods From May 2015 to May 2017, a total of 120 outpatient and inpatient patients with bronchial asthma during remission period treated in Department of Respiratory of the First Traditional Chinese Medicine Hospital in Changde City were selected and they were divided into the treatment group(n=60) and control group(n=60) according to the random number table method. Patients in the control group were treated with Salmeterol Roticasone Powder,while patients in the treatment group were treated with autohemotherapy via meridians. The efficacy and the asthma control test(ACT) score before and after treatment between the two groups were compared. Results There was no significant difference of the curative effect between the two groups(P>0.05). There was no significant difference in ACT score between the two groups before treatment, after treatment and follow-up for 1 month(P>0.05). The ACT score of the two groups after treatment was higher than that before treatment, and the difference was statistically significant(P<0.05). Follow-up for 1 month showed that ACT scores of the two groups were significantly higher than those before and after treatment, with statistical differences(P <0.05). Conclusion Both autohemotherapy and Salmeterol Roticasone Powder have curative effect in the treatment of asthma during remission period. There is no significant difference in the efficacy treated by autohemotherapy and Salmeterol Roticasone Powder therapy.
Objective To investigate the clinical effect of autohemotherapy in the treatment of bronchial asthma at remittent period. Methods From May 2015 to May 2017, a total of 120 outpatient and inpatient patients with bronchial asthma during remission period treated in Department of Respiratory of the First Traditional Chinese Medicine Hospital in Changde City were selected and they were divided into the treatment group(n=60) and control group(n=60) according to the random number table method. Patients in the control group were treated with Salmeterol Roticasone Powder,while patients in the treatment group were treated with autohemotherapy via meridians. The efficacy and the asthma control test(ACT) score before and after treatment between the two groups were compared. Results There was no significant difference of the curative effect between the two groups(P>0.05). There was no significant difference in ACT score between the two groups before treatment, after treatment and follow-up for 1 month(P>0.05). The ACT score of the two groups after treatment was higher than that before treatment, and the difference was statistically significant(P<0.05). Follow-up for 1 month showed that ACT scores of the two groups were significantly higher than those before and after treatment, with statistical differences(P <0.05). Conclusion Both autohemotherapy and Salmeterol Roticasone Powder have curative effect in the treatment of asthma during remission period. There is no significant difference in the efficacy treated by autohemotherapy and Salmeterol Roticasone Powder therapy.
引文
[1]赵彩霞.支气管哮喘发病机制的研究进展[J].医学理论与实践,2016,29(7):870-872.
[2]华雯,黄华琼,沈华浩.《支气管哮喘防治指南(2016年版)》解读[J].浙江大学学报(医学版),2016,45(5):447-452.
[3]田德禄.中医内科学[M].北京:人民卫生出版社,2011.
[4]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志,2016,39(9):675-697.
[5]盛荣.穴位注射治疗支气管哮喘的临床研究[J].世界最新医学信息文摘,2016,16(23):25-26.
[6]张林娇.支气管哮喘发病的危险因素及相关护理对策[J].首都食品与医药,2017,24(24):101.
[7]洪建国.2006年版全球哮喘防治创议[J].实用儿科临床杂志,2007,22(16):1278-1280.
[8]郑莉莉,李泽庚.中医文献对支气管哮喘病名病因病机的认识溯源[J].中国中医药现代远程教育,2016,14(4):141-143.
[9]杨玉萍.对洪广祥教授关于气阳虚弱为哮喘发病内因理论思考[J].中华中医药杂志,2016,31(11):4437-4438.
[10]杨兰,高泓.近十年自血疗法的临床研究概况[J].中医外治杂志,2017,26(2):53-54.
[11]颜蔓仪.自血穴位注射治疗哮喘及慢性支气管炎概况[J].实用中医药杂志,2003,6(6):332.
[12]刘海涛,张立德,刘玉丽.大鼠“肺俞”“心俞”穴定位研究[J].山西中医,2016,32(2):38,40.
[13]耿昊,占道伟,徐万里,等.针刺肺经腧穴、大肠经腧穴对支气管哮喘慢性持续期患者肺功能的影响[J].河南中医,2017,37(12):2191-2193.
[14]耿立梅,马璇雯,于向艳,等.穴位注射联合中药贴敷对哮喘大鼠细胞因子IL-10、IL-17的影响[J].四川中医,2017,35(12):42-44.
[15]吴兆利,李春日,刘自力,等.针刺“足三里”对哮喘大鼠嗜酸陛粒细胞凋亡及相关基因表达的影响叨[J].中国针灸,2012,32(8):721-725.
[2]华雯,黄华琼,沈华浩.《支气管哮喘防治指南(2016年版)》解读[J].浙江大学学报(医学版),2016,45(5):447-452.
[3]田德禄.中医内科学[M].北京:人民卫生出版社,2011.
[4]中华医学会呼吸病学分会哮喘学组.支气管哮喘防治指南(2016年版)[J].中华结核和呼吸杂志,2016,39(9):675-697.
[5]盛荣.穴位注射治疗支气管哮喘的临床研究[J].世界最新医学信息文摘,2016,16(23):25-26.
[6]张林娇.支气管哮喘发病的危险因素及相关护理对策[J].首都食品与医药,2017,24(24):101.
[7]洪建国.2006年版全球哮喘防治创议[J].实用儿科临床杂志,2007,22(16):1278-1280.
[8]郑莉莉,李泽庚.中医文献对支气管哮喘病名病因病机的认识溯源[J].中国中医药现代远程教育,2016,14(4):141-143.
[9]杨玉萍.对洪广祥教授关于气阳虚弱为哮喘发病内因理论思考[J].中华中医药杂志,2016,31(11):4437-4438.
[10]杨兰,高泓.近十年自血疗法的临床研究概况[J].中医外治杂志,2017,26(2):53-54.
[11]颜蔓仪.自血穴位注射治疗哮喘及慢性支气管炎概况[J].实用中医药杂志,2003,6(6):332.
[12]刘海涛,张立德,刘玉丽.大鼠“肺俞”“心俞”穴定位研究[J].山西中医,2016,32(2):38,40.
[13]耿昊,占道伟,徐万里,等.针刺肺经腧穴、大肠经腧穴对支气管哮喘慢性持续期患者肺功能的影响[J].河南中医,2017,37(12):2191-2193.
[14]耿立梅,马璇雯,于向艳,等.穴位注射联合中药贴敷对哮喘大鼠细胞因子IL-10、IL-17的影响[J].四川中医,2017,35(12):42-44.
[15]吴兆利,李春日,刘自力,等.针刺“足三里”对哮喘大鼠嗜酸陛粒细胞凋亡及相关基因表达的影响叨[J].中国针灸,2012,32(8):721-725.